BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19, a news release said. AZD7442 is currently in Phase-I clinical studies and AstraZeneca plans to advance the LAAB combination into Phase-3 trials in the coming weeks. The agreement enables…
Tag: Lonza
Lonza appoints Pierre-Alain Ruffieux as new Chief Executive Officer
BASEL, SWITZERLAND: The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals. Albert Baehny, Chairman of the Board said: “The Board is delighted to have appointed someone…
Moderna and Lonza announce strategic collaboration to manufacture vaccine against Novel Coronavirus
BASEL, SWITZERLAND: Moderna Inc., a clinical stage biotechnology company, and Lonza Ltd. have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies plan to establish manufacturing suites at…
Lonza expands Bioconjugation facility and announces approval of third commercial ADC
BASEL, SWITZERLAND: Lonza has announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion will meet the development and manufacturing needs of pharma and biotech…